Feb. 5, 2025 — Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful ...

Bavarian Nordic is now catching up to Valneva, whose Ixchiq vaccine became the world’s first licensed chikungunya vaccine when it was approved by the US Food and Drug Administration (FDA ...

Credit: Soumyabrata Roy via Getty Images. Bavarian Nordic’s chikungunya vaccine Vimkunya is one step closer to being available in Europe after having secured an European Medicines Agency (EMA) ...

In these cases, the label on the vaccine vial had also been falsified. The Vaccine Identify Evaluation (VIE) Collaboration are developing novel tests for detecting falsified vaccines in supply chains.

We observed tasks in the vaccine preparation process, from the time of removal of the vial or the syringe package from the refrigerator until the time it was ready to be administered to a patient.

This allocation is for supplies of vaccines, syringes and cold chain equipment to states and UTs to enable them to reach all children under the Universal Immunization Programme (UIP). India runs ...

The hepatitis B vaccine is a shot, typically injected into the arm, that protects against hepatitis B in babies, children, and adults. It is an important way to protect yourself and your children from ...

Valneva's Ixchiq is the first and only approved Chikungunya vaccine in the US, Canada, and EU. Ixiaro is for Japanese encephalitis, and it’s today VALN’s main revenue contributor. But its near ...

today announced positive results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ ®, in 304 children.

In the OR, an anesthesiologist takes a vial of medication, combines it with a diluent in a syringe, and a label is then produced for that syringe so the anesthesiologist can confirm what is being ...

Already approved in those aged 18 and older in the United States, Valneva has submitted label extension applications to the FDA for IXCHIQ use in adolescents aged 12 to 17 years. Valneva's single-shot ...